SMT201500132B - Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate - Google Patents
Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associateInfo
- Publication number
- SMT201500132B SMT201500132B SM201500132T SM201500132T SMT201500132B SM T201500132 B SMT201500132 B SM T201500132B SM 201500132 T SM201500132 T SM 201500132T SM 201500132 T SM201500132 T SM 201500132T SM T201500132 B SMT201500132 B SM T201500132B
- Authority
- SM
- San Marino
- Prior art keywords
- hepatitis
- virus
- bda
- treatment
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470666P | 2011-04-01 | 2011-04-01 | |
PCT/EP2012/055857 WO2012131061A1 (en) | 2011-04-01 | 2012-03-30 | Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201500132B true SMT201500132B (it) | 2015-07-09 |
Family
ID=45952512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201500132T SMT201500132B (it) | 2011-04-01 | 2015-06-10 | Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate |
Country Status (22)
Country | Link |
---|---|
US (3) | US20140011736A1 (xx) |
EP (2) | EP2694087B1 (xx) |
JP (1) | JP2014509630A (xx) |
KR (1) | KR20140010097A (xx) |
CN (1) | CN103458913A (xx) |
AU (2) | AU2012237295A1 (xx) |
BR (1) | BR112013024809A2 (xx) |
CA (1) | CA2831675A1 (xx) |
CY (1) | CY1116374T1 (xx) |
DK (1) | DK2694087T3 (xx) |
ES (1) | ES2533213T3 (xx) |
HK (1) | HK1193571A1 (xx) |
HR (1) | HRP20150430T1 (xx) |
MX (1) | MX2013011411A (xx) |
PL (1) | PL2694087T3 (xx) |
PT (1) | PT2694087E (xx) |
RS (1) | RS53911B1 (xx) |
RU (1) | RU2013148779A (xx) |
SI (1) | SI2694087T1 (xx) |
SM (1) | SMT201500132B (xx) |
TW (1) | TW201247216A (xx) |
WO (1) | WO2012131061A1 (xx) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120208746A1 (en) * | 2011-01-12 | 2012-08-16 | Scynexis Inc. | Genetic markers associated with response to cyclophilin-binding compounds |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
EP3226973A4 (en) * | 2014-12-04 | 2018-05-30 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
EP3285768B1 (en) | 2015-04-21 | 2020-12-30 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
RU2662161C1 (ru) * | 2017-08-11 | 2018-07-24 | Васильевич Иващенко Александр | Ингибитор входа вируса гепатита и фармацевтическая композиция для лечения гепатита |
CA3109955A1 (en) * | 2018-08-23 | 2020-02-27 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection with interferon lambda |
CN114051411B (zh) * | 2019-07-18 | 2022-10-28 | 埃尼奥制药公司 | Eyp001与ifn用于治疗hbv感染的协同效应 |
IL293892A (en) * | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists to treat hepatitis d virus infection |
CN113662945A (zh) * | 2020-05-15 | 2021-11-19 | 福建广生堂药业股份有限公司 | 用于治疗乙型肝炎的组合 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
CA1338800C (en) * | 1986-06-17 | 1996-12-17 | Michael Houghton | Hepatitis delta and diagnostics and vaccines |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
ES2174915T3 (es) | 1993-11-10 | 2002-11-16 | Enzon Inc | Productos de conjugacion mejorados de un interferon con un polimero. |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
RS51614B (en) | 2004-10-01 | 2011-08-31 | Debiopharm S.A. | USE OF [D-MEAL] 3- [ETVAL] 4-CYCLOSPORINE FOR THE TREATMENT OF HEPATITIS C INFECTIONS |
AU2005322242B2 (en) | 2004-12-23 | 2010-02-11 | Novartis Ag | Compositions for HCV treatment |
-
2012
- 2012-03-30 EP EP12713680.2A patent/EP2694087B1/en active Active
- 2012-03-30 ES ES12713680.2T patent/ES2533213T3/es active Active
- 2012-03-30 TW TW101111555A patent/TW201247216A/zh unknown
- 2012-03-30 MX MX2013011411A patent/MX2013011411A/es not_active Application Discontinuation
- 2012-03-30 BR BR112013024809A patent/BR112013024809A2/pt not_active IP Right Cessation
- 2012-03-30 JP JP2014501660A patent/JP2014509630A/ja active Pending
- 2012-03-30 CA CA2831675A patent/CA2831675A1/en not_active Abandoned
- 2012-03-30 PL PL12713680T patent/PL2694087T3/pl unknown
- 2012-03-30 SI SI201230181T patent/SI2694087T1/sl unknown
- 2012-03-30 CN CN2012800172986A patent/CN103458913A/zh active Pending
- 2012-03-30 RU RU2013148779/15A patent/RU2013148779A/ru not_active Application Discontinuation
- 2012-03-30 DK DK12713680T patent/DK2694087T3/en active
- 2012-03-30 PT PT127136802T patent/PT2694087E/pt unknown
- 2012-03-30 WO PCT/EP2012/055857 patent/WO2012131061A1/en active Application Filing
- 2012-03-30 US US14/007,468 patent/US20140011736A1/en not_active Abandoned
- 2012-03-30 EP EP15190917.3A patent/EP3006037A1/en not_active Withdrawn
- 2012-03-30 RS RS20150233A patent/RS53911B1/en unknown
- 2012-03-30 AU AU2012237295A patent/AU2012237295A1/en not_active Abandoned
- 2012-03-30 KR KR1020137025396A patent/KR20140010097A/ko not_active Application Discontinuation
-
2014
- 2014-07-10 HK HK14107028.5A patent/HK1193571A1/xx not_active IP Right Cessation
- 2014-07-28 US US14/444,418 patent/US20150023917A1/en not_active Abandoned
-
2015
- 2015-04-20 HR HRP20150430TT patent/HRP20150430T1/hr unknown
- 2015-04-24 CY CY20151100380T patent/CY1116374T1/el unknown
- 2015-06-10 SM SM201500132T patent/SMT201500132B/xx unknown
- 2015-10-07 US US14/877,241 patent/US20160101146A1/en not_active Abandoned
-
2016
- 2016-03-24 AU AU2016201888A patent/AU2016201888A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CY1116374T1 (el) | 2017-02-08 |
RU2013148779A (ru) | 2015-05-10 |
AU2016201888A1 (en) | 2016-04-21 |
SI2694087T1 (sl) | 2015-05-29 |
HK1193571A1 (en) | 2014-09-26 |
WO2012131061A1 (en) | 2012-10-04 |
JP2014509630A (ja) | 2014-04-21 |
EP2694087A1 (en) | 2014-02-12 |
EP3006037A1 (en) | 2016-04-13 |
KR20140010097A (ko) | 2014-01-23 |
HRP20150430T1 (hr) | 2015-05-22 |
PT2694087E (pt) | 2015-04-09 |
BR112013024809A2 (pt) | 2016-09-06 |
RS53911B1 (en) | 2015-08-31 |
CA2831675A1 (en) | 2012-10-04 |
ES2533213T3 (es) | 2015-04-08 |
EP2694087B1 (en) | 2015-01-28 |
US20140011736A1 (en) | 2014-01-09 |
CN103458913A (zh) | 2013-12-18 |
US20160101146A1 (en) | 2016-04-14 |
US20150023917A1 (en) | 2015-01-22 |
PL2694087T3 (pl) | 2015-06-30 |
DK2694087T3 (en) | 2015-04-13 |
MX2013011411A (es) | 2014-04-14 |
AU2012237295A1 (en) | 2013-09-19 |
TW201247216A (en) | 2012-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201500132B (it) | Trattamento dell'infezione da virus dell'epatite bda solo o in combinazione con virus dell'epatite delta e delle patologie epatiche associate | |
BR112013020425A2 (pt) | composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b | |
SMT201300043B (it) | Inibitori del virus dell'epatite c | |
NZ702744A (en) | D-amino acid compounds for liver disease | |
SMT201600470B (it) | Inibitori del virus dell'epatite c | |
BRPI1010506A2 (pt) | "inibidores do vírus da hepatite c" | |
SMT201700029B (it) | Inibitori del virus dell'epatite c | |
BR112013030045A2 (pt) | composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente | |
DK3495387T3 (da) | Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme | |
MX2012011222A (es) | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. | |
CO6970603A2 (es) | Composiciones y métodos para tratar el virus de la hepatitis c | |
HK1197026A1 (en) | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection | |
EP2536425A4 (en) | VACCINES FOR USE IN PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUS DISEASE | |
GB2548034B (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
DK2917231T3 (da) | Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme | |
SMT201700028B (it) | Composti benzofuranici per il trattamento delle infezioni da virus dell’epatite c | |
FI20135146L (fi) | Farmaseuttiset koostumukset ja hoitomenetelmät | |
BR112014007963A2 (pt) | aminotiazoles substituídos como inibidores de cãncer, incluindo carcinoma hepatocelular, e como inibidores da replicação do vírus da hepatite | |
GB2497453B (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
HK1201262A1 (en) | Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection (hcv) | |
BR112013024904A2 (pt) | composto e método ex vivo de redução da infecciosidade ou de inativação de um vírus da hepatite c | |
BR112013013166A2 (pt) | tratamentos da infecção pelo vírus da hepatite c | |
SI2537528T1 (sl) | Farmacevtski sestavki, ki vsebujejo beta- in alfa-galaktozidazo in njihova uporaba v zdravljenju gastroezofagealne refluksne bolezni | |
BR112013025934A2 (pt) | tratamento de infecção pelo vírus da hepatite c com alisporivir | |
ITTO20110635A1 (it) | Composizione farmaceutica di combinazione e metodi per trattare e prevenire le malattie infettive |